This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Brighter Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

-42.0%

Groei van de winst

-5.3%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	4.3%
Inkomstengroei	11.8%
Rendement op eigen vermogen	-85.9%
Nettomarge	-556.2%
Volgende winstupdate	29 Nov 2022

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Brighter geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:2HJ Opbrengsten, kosten en inkomsten (SEK Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 22	33	-184	146
31 Mar 22	38	-208	156
31 Dec 21	42	-210	165
30 Sep 21	48	-257	176
30 Jun 21	47	-246	175
31 Mar 21	57	-231	190
31 Dec 20	56	-221	190
30 Sep 20	58	-162	186
30 Jun 20	50	-142	157
31 Mar 20	39	-111	122
31 Dec 19	37	-90	102
30 Sep 19	36	-68	84
30 Jun 19	32	-66	80
31 Mar 19	28	-58	74
31 Dec 18	26	-53	70
30 Sep 18	29	-46	70
30 Jun 18	28	-41	63
31 Mar 18	33	-33	61
31 Dec 17	31	-27	53
30 Sep 17	25	-26	47
30 Jun 17	28	-21	46
31 Mar 17	24	-17	42
31 Dec 16	25	-15	42
30 Sep 16	23	-15	37
30 Jun 16	23	-14	36
31 Mar 16	21	-12	32
31 Dec 15	16	-11	26

Kwaliteitswinsten: 2HJ is currently unprofitable.

Groeiende winstmarge: 2HJ is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 2HJ is unprofitable, and losses have increased over the past 5 years at a rate of 42% per year.

Versnelling van de groei: Unable to compare 2HJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: 2HJ is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-37.2%).

Rendement op eigen vermogen

Hoge ROE: 2HJ has a negative Return on Equity (-85.88%), as it is currently unprofitable.

This company listing is no longer active

Brighter Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023

Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021)

First quarter 2022 earnings released: kr0.07 loss per share (vs kr0.20 loss in 1Q 2021)

Full year 2021 earnings released: kr0.60 loss per share (vs kr1.08 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Brighter AB (publ) to Report Fiscal Year 2021 Results on Apr 13, 2022

Recent updates

Nasdaq Stockholm AB Decides to Delist the Shares and Equity Rights of Brighter AB

Nasdaq Stockholm imposes a fine on Brighter AB (publ)

Brighter AB (Publ) Applies for Corporate Restructuring in Bid for Longer-Term Financing

Brighter AB (publ) Announces Executive Changes

Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023

Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021)

Brighter AB (Publ.) Announces its Actiste® Receives Telecommunication Type Approval in the United Arab Emirates

High number of new and inexperienced directors

Brighter AB (publ) Receives Final Approvals for Pilot Research with Insulin-Treated Diabetes Patients in the UAE

High number of new and inexperienced directors

Brighter's Interim CEO Erik Lissner Takes Permanent Role as the Company CEO

Brighter AB Announces Actiste®, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar

700Brighter AB Announces Actiste, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar

Brighter AB (Publ) Announces Appointment of Johnny Ludvigsson as Board Member

Brighter AB (publ) Announces First Patient Recruited for the Actiste Study in the United Kingdom

First quarter 2022 earnings released: kr0.07 loss per share (vs kr0.20 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: kr0.60 loss per share (vs kr1.08 loss in FY 2020)

Brighter AB (Publ) Announces Launch and Commercial Availability of its Actiste® Service, Aiming to Improve the Quality of Life for People Living with Diabetes in Qatar

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Brighter AB (publ) to Report Fiscal Year 2021 Results on Apr 13, 2022

Brighter AB (publ) to Report Q3, 2022 Results on Nov 09, 2022

Brighter AB (publ), Annual General Meeting, May 05, 2022

Brighter AB (publ) has completed a Composite Units Offering in the amount of SEK 117.093404 million.

Brighter AB (publ) announces positive results for Actiste®

A shareholder of Blodtrycksdoktorn AB entered into an agreement to acquire an unknown stake in Blodtrycksdoktorn AB from Brighter AB (publ) (OM:BRIG) for SEK 5 million.

Beijing AddLife AB (publ) (OM:ALIF B) acquired Camanio AB from Brighter AB (publ) (OM:BRIG) for SEK 65 million.

Third quarter 2021 earnings released: kr0.20 loss per share (vs kr0.18 loss in 3Q 2020)

Brighter's Actiste Receives Final Outstanding Approval in Qatar

Interim Chief Financial Officer Julie Silber has left the company

Second quarter 2021 earnings released: kr0.20 loss per share (vs kr0.27 loss in 2Q 2020)

Brighter's Actiste Receives Telecommunication Approval in Qatar

Brighter's Actiste Mini Receives Telecommunication Approval in Qatar

Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actiste

Brighter AB (Publ) Launches Innovative Pilot Project with Tomelilla Municipality

Brighter AB (Publ) Provides Revenue Guidance for the Year 2021

Brighter AB (Publ) Makes Progress with the User Experience Test of the Diabetes Management Solution Actiste

First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)

Brighter AB (Publ) Announces the Patent to Safely Combine MDD and IVDD Functionality into One Unit

Full year 2020 earnings released: kr1.04 loss per share (vs kr1.06 loss in FY 2019)

Brighter AB (publ) to Report Q4, 2021 Results on Feb 20, 2022

Brighter Signs 5-Year Distribution Agreement for Actiste in Qatar

Brighter AB (publ) Announces CEO Changes

Brighter AB (publ) Announces Diabetes Management Devices Actiste and Actiste Mini Receives Market Approval in Thailand

Brighter AB (publ) Announces Clarification of Information Regarding Agreements for Nigeria and Ghana

Brighter AB (publ) Signs 5-Year Agreement with Wssonlines Nigeria Ltd and Receives Initial Order for Actiste® Worth Eur 2.3 Million in Nigeria

Brighter AB (publ)'s Actiste® Mini Receives Market Approval in the Kingdom of Saudi Arabia

Brighter AB (Publ) Announces Nomination Committee for the AGM 2021

New 90-day high: €0.31

Brighter AB (publ) Announces Executive Changes

Brighter's Pioneering Diabetes Management Solution Actiste® Receives Market Approval in the United Arab Emirates

Third quarter 2020 earnings released: kr0.16 loss per share

Brighter AB (Publ) Announces Actiste Device and Its Associated Digital Platform Received Market Approval from the Saudi Food and Drug Authority

Founder & Executive Director recently sold €143.8k worth of stock

First half earnings released

First half earnings released

Brighter AB (publ) to Report Q4, 2020 Results on Feb 12, 2021

New 90-day low - €0.30

New 90-day low - €0.30

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden